Additional file 1: of Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Kim Papp
Robert Bissonnette
Melinda Gooderham
Steven Feldman
Lars Iversen
Jennifer Soung
Zoe Draelos
Carla Mamolo
Vivek Purohit
Cunshan Wang
William Ports
10.6084/m9.figshare.c.3627356_D2.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Treatment_of_plaque_psoriasis_with_an_ointment_formulation_of_the_Janus_kinase_inhibitor_tofacitinib_a_Phase_2b_randomized_clinical_trial/4412861
Figure S1. Change from baseline in DLQI through Week 16. Table S1. Serious adverse events by treatment group. Table S2. Number and percent of plasma tofacitinib concentration samples (pre-dose and post-dose) by concentration range â available data mild/moderate - post hoc. Table S3. Summary of plasma tofacitinib pharmacokinetic parameters - available data at week 4 - mild/moderate - post hoc. (DOCX 238Â kb)
2016-10-03 05:00:00
Psoriasis
Topical
Tofacitinib
CP-690,550
Physicianâs Global Assessment
Psoriasis Area and Severity Index
PASI
Dermatology Life Quality Index
Pruritus
Itch